Skip to content

Assessing Quality of Life in PSC

Quality of Life Evaluation Workshop

Warsaw, Poland

Friday 19 September 2025

Last week, Mark Chatterley and I travelled to Poland to represent PSC patients at a workshop to bring together researchers working on measuring quality of life in PSC. The workshop was organised by Professor Doug Thorburn (University College London), Prof. Shivani Sharma (Aston University) and Dr. Maciej Janik (Medical University Warsaw), and funded by the ERN RARE-LIVER. Pharmaceutical companies and the European Medicines Agency were also represented.

Credit: Medical University of Warsaw, Poland
Credit: Medical University of Warsaw, Poland

Our surveys tell us that the most difficult aspect of living with PSC is the unpredictability of PSC and uncertainty about the future, as well as the long term, daily symptoms. Over time, they add up and become debilitating for some.

 

We urgently need a way to measure quality of life in PSC that captures the true impact of the disease. Mark’s outstanding presentation of his personal story conveyed the long-lasting and far reaching effects of PSC, showing the disease is so much more than medical test results.

Mark presenting at the QoL workshop

PSC Support has funded Ryan James' ongoing research to develop a quality of life tool and Alice Freer’s research training fellowship to understand fatigue. PSC Partners Seeking a Cure is also funding exciting work to develop ways to properly capture our experience of certain symptoms (pain, fatigue and brain fog). Many who live with these symptoms know that a simple score out of ten doesn’t really tell the full story.

 

There’s a lot of research work exploring different dimensions of quality of life and it is important that we’re aligned and collaborating where possible. There are strict regulatory standards to meet and creating multi-cultural tools is expensive.

 

Three highlights for me were:

  • The shared determination to collaborate and keep the momentum of the workshop going.
  • It was especially encouraging to see industry openness to considering the use of these tools to measure drug effectiveness (efficacy) in trials. Properly designed tools could be a real game changer, helping to attract more pharmaceutical investment into PSC.
  • The importance of patient involvement. I am sure Mark’s presentation touched our researchers and drove a genuine will to work even harder and to collaborate with a new sense of urgency. This workshop was an important step forward and the patient voice is being heard more strongly than ever.

 

Ultimately, I’d like to see new tools that can assess patient experience used to improve:

  • PSC healthcare: justifying much-needed routine psychological support and
  • clinical trials by providing a new way to assess the effect of treatments.
Mark at Worksop 19 Sep

Do drop me an email if you have any questions:

Martine Walmsley

PSC Support Head of Research Strategy
ERN RARE-LIVER Management Board and PSC Working Group Co-Lead

martine@pscsupport.org.uk